Home Page  | Upcoming Events  |  Past Events  |  Registration  |   Attendees  |  More Info  |  LinkedIn
Predicting Medication Adherence:  Implications for Readmissions and Overall Outcomes 
  Download Brochure Need a brochure? Download the event brochure including a registration form you can fax or mail
Since the days of Hippocrates, medication non-adherence has been a significant health care problem. Recent research suggests that the total economic cost of non-adherence is $290 billion per year in the United States, rivaling the burden of cardiovascular disease. New quality measures have been established and implemented by CMS offering health plans unprecedented financial bonuses from improving medication adherence at a population level. Moreover, the cost effectiveness of efforts to improve adherence have never been greater given recent reductions in the average cost of many common chronic disease drug therapies due to the expiration of patent protection for many blockbuster drugs.

From another perspective, preventable hospital readmissions are a threat to patient safety, a burden to numerous stakeholders, occur far too often, and contribute to rising health care costs. Nationally, preventable readmissions cost an estimated $25 billion per year. Hospitals, attending physicians and other providers have been focusing on reducing preventable readmissions, as they seek to improve quality and improve outcomes, and due to Medicare policy and payment changes in this regard. Health plans, employers, care management organizations and other stakeholders also have a significant vested interest in managing readmissions for all applicable patient populations.

Despite recent momentum addressing medication adherence, major progress on improving adherence nationally is lacking because of the difficulty of identifying the specific patients who could most benefit from care management support to address common causes of non-adherence. Readmissions management also is challenged by the ability to predict those most as risk for readmission.

This session connects the dots between the issues of Medication Adherence, Readmissions Management and Predictive Analytics; providing insight into the correlation between medication adherence and readmissions; the application of predictive models for medication adherence; and the implications for improving outcomes, efficiencies and performance in a variety of care settings and scenarios by through identification of those at risk for low medication adherence.

Join us on Wednesday, March 13th, 2013, as Blue Cross & Blue Shield Rhode Island's Doctor Brian Wolf discusses their analytics initiative that correlated medication adherence with readmissions, and their continuing efforts to leverage resulting improvements in their readmissions management. Doctor Wolf's presentation will be followed by Aaron McKethan, PhD of RxAnte's examination of how an analytic platform that starts with a robust calibration process, claims and clinical data, and accurate predictions, results in the more efficient achievement of better outcomes than targeting strategies based on lagging adherence indicators.
Learning Objectives
Participants will be able to:
  1. Understand the correlation between readmissions by number of days between discharge and the discharge prescription fill date.
  2. Consider the implications for readmissions management through application of predictive models to identify those at risk for low post-discharge medication adherence.
  3. Identify best practices for using advanced analytics to provide more accurate prediction rates for medication adherence on an individual level.
  4. Review results that can be achieved through a system that ties these individual predictions to individual intervention recommendations.
  5. Ascertain the importance of using predictive modeling rather than lagging indicators to forecast adherence rates.
  6. Engage in interactive learning through online question submission, attendee feedback and opportunity for follow-up questions, and networking with attendees, faculty and other professionals through a dedicated LinkedIn group.
Who Should Attend

Interested attendees would include:

  • C-Suite Executives
  • Medical Directors
  • Care Management Executives
  • Analytics and Informatics Executives and Staff
  • Readmissions Management Executives
  • Pharmaceutical Management Executives and Staff
  • Strategy and Planning Executives and Staff
  • Innovation and Transformation Executives
  • Business Intelligence Staff
  • Other Interested Parties

Attendees would represent organizations including:

  • Health Plans 
  • Hospitals and Health Systems
  • Provider Networks
  • Accountable Care Organizations
  • Pharmaceutical Organizations
  • PBMs
  • Other Healthcare Providers
  • Care Management Organizations
  • Third Party Administrators
  • Employers
  • Solutions Providers 
  • State and Local Government Agencies
  • Associations, Institutes and Research Organizations 
  • Media
  • Other Interested Organizations

Predicting Medication Adherence:  Implications for Readmissions and Overall Outcomes 
  Individual Registration Fee: $195. webinar flash drive with video syncing slides and recorded audio, plus presentation pdf file: $45 for attendees; $260 for non-attendees after the event. Register online or download the event brochure.
Register Now   Corporate Site licensing also available. Click here to register or call 209.577.4888 We look forward to your participation in this event!
Brian Wolf, MD

Brian E. Wolf, MD
Senior Medical Director
Health Management Integration
Blue Cross & Blue Shield, Rhode Island

Dr. Brian Wolf is the Senior Medical Director for Health Analytics and Utilization Management, with additional oversight of Physician Profiling and Audit and Recovery, at Blue Cross Blue Shield of Rhode Island. He also serves as Physician Advisor for Wellpoint with responsibility for Utilization Management of the Unicare product.

Previously he was site Chief of Surgery and Surgical Oncologist, as well as Division Chief of General Surgery for the Cambridge Health Alliance from 2002-2007. From 2000-2002 he served as Surgical Oncologist and Director of Surgical Services for Tri-County Medical Associates From 1989 to 1999 he was Surgical Oncologist and Chairman of Physician Executive Council for Harvard Pilgrim Health Care of New England.

Dr. Wolf received his Doctor of Medicine from Boston University School of Medicine, Boston, Massachusetts and is Board Certified in General Surgery.

Aaron McKethan, PhD

Aaron McKethan, PhD
Senior Vice President for Strategy and Business Development
  Aaron McKethan is Senior Vice President for Strategy and Business Development for RxAnte. His areas of expertise include provider payment, quality improvement, and health IT.

Before joining RxAnte, Dr. McKethan was Director of the Beacon Community program, a $250 million federal health IT demonstration project at the Office of the National Coordinator for Health IT in the Department of Health and Human Services. Previously, he served as a Research Director for the Engelberg Center for Health Care Reform at the Brookings Institution in Washington, DC, where he focused on new payment models designed to lower per-capita costs and improve health-care outcomes.

Dr. McKethan earned Bachelor of Arts and PhD degrees at the University of North Carolina at Chapel Hill, where he is currently Assistant Adjunct Professor of Health Policy and Management at the Gillings School of Global Public Health. He is also a visiting scholar at the Brookings Institution.

HealthcareWebSummit events from MCOL  
1101 Standiford Ave. Suite C-3 Modesto, CA 95350
Phone 209.577.4888  | e-Mail  |  Fax 209.577.3557
copyright , MCOL All rights reserved. Terms of Use apply to this site and participation in events.